Trastuzumab-DM1 comprises ImmunoGen’s cell-killing agent, DM1, linked to Genentech’s HER2-targeting antibody, Herceptin (trastuzumab), and is in development by Genentech for the potential treatment of HER2-expressing metastatic breast cancer.
Mitchel Sayare, chairman and CEO of ImmunoGen, said: “We’re delighted with the progress Genentech is making in their development of trastuzumab-DM1 and with the clinical findings reported to date. We anticipate sustained growth over time in the number of TAP compounds in clinical testing and in those advancing to later stage trials. In fact, phase II testing of our wholly-owned huC242-DM4 TAP compound is expected to begin imminently.”
The phase II study now underway assesses trastuzumab-DM1 in patients with HER2-expressing metastatic breast cancer that has progressed on treatment with Herceptin (trastuzumab) plus chemotherapy.
The milestone was earned under the 2000 agreement granting Genentech the exclusive right to develop products using ImmunoGen’s maytansinoid TAP technology and linkers with therapeutic antibodies to HER2, as amended in 2006 to enable ImmunoGen to earn increased milestone payments with achievement of agreed upon process development milestones. Genentech is responsible for product development, manufacturing, and commercialization.